Short-term efficacy of levosimendan combining recombinant human brain natriuretic peptide on heart ;failure after old myocardial infarction

Hong-zhen TIAN,Jiang CHEN,Zhi-jun SUN,Guang-hui CHEN

DOI: https://doi.org/10.3969/j.issn.1674-4055.2015.06.16

2015-01-01

Abstract:Objective To observe the curative effect and safety of levosimendan combining recombinant human brain natriuretic peptide (rhBNP) on heart failure after old myocardial infarction (OMI). Methods The patients (n=60, male 39, female 21, aged from 49 to 78 and average age=68.2±13.1) were chosen from Dec. 2012 to Jun. 2014. All patients were randomly divided into control group and treatment group (each n=30). Besides of basic therapy was given to 2 groups, control group was additionally given levosimendan and treatment group was given levosimendan and rh-BNP. The hemodynamic indexes including cardiac output (CO), cardiac index (CI), intrathoracic blood volume index (ITBVI) and extravascular lung water index (EVLWI) were monitored with pulse-indicated continuous cardiac output (PiCCO). The levels of LVEF, LVEDd and brain natriuretic peptide (BNP) were detected and heart function was reviewed by using 6-minute walk test (6MWT) before and 7 d after treatment, and incidence of adverse reactions were observed. Results The levels of CO and CI increased significantly and ITBVI and EVLWI decreased significantly in 2 groups 72 h after treatment (all P<0.05). In treatment group, CO [(4.43±0.36) L/min vs. (3.44±0.13) L/min], CI [(4.57±0.64) L/min·m2 vs. (3.45±0.24) L/min·m2], ITBVI [0.72±0.08) L·m2 vs. (0.96±0.07) L·m2], and EVLWI [(5.70±0.32) mL/kg vs. (7.39±0.76) mL/kg] were better significantly than those in control group (all P<0.05). The fluid in-put and out-put volume was significantly more in treatment group than that in control group (P<0.05). The levels of LVEF and 6MWD increased significantly, and LVEDD and BNP decreased significantly in 2 group 7 d after treatment (all P<0.05). After treatment, LVEF [(36.71±3.24)%vs. (39.51±3.19)%] and 6MWD [(236.75± 58.39) m vs. (267.94±42.13) m] increased, and LVEDD [(54.3±2.4) mm vs. (51.6±3.8) mm] and BNP [(2936.81±1052.47) pg/mL vs. (2438.65±824.2) pg/mL] decreased in treatment group compared with control group (all P<0.05). The incidence of adverse reactions had no statistical difference between 2 groups (P>0.05). Conclusion Levosimendan combining rhBNP is superior to single levosimendan in improve hemodynamics and heart function in patients with heart failure after OMI with higher safety.